Cargando…

Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication

The authors describe one case of anterior uveitis after treatment of age-related macular degeneration with both antiangiogenic drugs: ranibizumab and bevacizumab. The case is described as a complication of ranibizumab and bevacizumab due to an inflammatory process. Several reasons are suggested to e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damasceno, Nadyr, Horowitz, Soraya, Damasceno, Eduardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422141/ https://www.ncbi.nlm.nih.gov/pubmed/22927728 http://dx.doi.org/10.2147/OPTH.S31239

Ejemplares similares

Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis(®))
por: Horowitz, Soraya Alessandra, et al.
Publicado: (2020)

Emphysema following vitrectomy with fluid–gas exchange: description of a rare complication
por: Damasceno, Eduardo F, et al.
Publicado: (2014)

Prevalence and factors associated with scleral hyaline plaque: clinical study of older adults in southeastern Brazil
por: Horowitz, Soraya, et al.
Publicado: (2015)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Karagiannis, Dimitrios A, et al.
Publicado: (2009)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab
por: Antonopoulos, Christina, et al.
Publicado: (2011)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
por: Schauwvlieghe, A. M. E., et al.
Publicado: (2016)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Diathermy for 23-gauge sclerotomy: a functional and morphologic study to avoid ocular hypotony
por: Horowitz, Soraya, et al.
Publicado: (2019)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
por: Biswas, Partha, et al.
Publicado: (2011)

Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
por: Kodjikian, Laurent, et al.
Publicado: (2014)

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
por: Topal, Tuncay, et al.
Publicado: (2017)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Spitzer, Martin S, et al.
Publicado: (2008)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration
por: Rishi, Ekta, et al.
Publicado: (2016)

How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
por: Empeslidis, Theodoros, et al.
Publicado: (2019)

Acquired unilateral rubella retinopathy in adult
por: Damasceno, Nadyr, et al.
Publicado: (2011)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
por: Dakin, Helen A, et al.
Publicado: (2014)

Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis
por: Wang, Wei, et al.
Publicado: (2014)

Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
por: Slean, Geraldine R., et al.
Publicado: (2016)

Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
por: Wang, Zongyi, et al.
Publicado: (2020)

Combined hamartoma of the retina and retinal pigment epithelium associated with optic coloboma
por: Damasceno, Nadyr Antonia, et al.
Publicado: (2011)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Mukherjee, Chandoshi, et al.
Publicado: (2015)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
Publicado: (2016)

Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
por: Kaiser, Peter K.
Publicado: (2007)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Rotsos, Tryfon, et al.
Publicado: (2010)

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
por: Chen, Youxin, et al.
Publicado: (2012)

Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
por: Otsuji, Tsuyoshi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_iorf8h44gcq65ie29tbmfsstou